

Abbott, Abbvie, Alexion, Amgen, ASN (American Society of Nephrology), Astra-Zeneca, Aveo, Chugai, DaVita, Fresenius, Genentech, Haymarket Media, Hofstra Medical School, IFKF (International Federation of Kidney Foundations), ISH (International Society of Hemodialysis), International Society of Renal Nutrition & Metabolism (ISRNM), JSDT (Japanese Society of Dialysis Therapy), Hospira, Kabi, Keryx, Novartis, NIH (National Institutes of Health), NKF (National Kidney Foundations), Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, Vifor, UpToDate, ZS-Pharma.

## **Objectives**

- 1. To examine pathophysiology and clinical implications of protein-energy wasting, sarcopenia, cachexia and malnutrition in CKD with focus on dialysis patients (ESRD).
- 2. To discuss role of serum albumin as a potential maker in PEW
- 3. To review data on high protein intake and IDPN in CKD patients on dialysis.

3

### Nutritional and Dietary Management of Kidney Disease: A Patient Care Approach

- We are what we eat: Learn how to enforce kidney health through nutrition and diet
- Saturday, Feb. 29, 2020 7:30 am 4:45 pm
- University of California Irvine (UCI) Medical Center, Bldg. 53, Auditorium 101
- The City Drive South, Orange, California 92868, USA
- UCI Nephrology has teamed up with the nation's leading experts to leverage their interests and expertise to provide insights on real-world clinical management and hands-on workshops for dietary approaches.
- This is a full-day CME course for physicians (nephrologists, internists, urologists and family practitioners) and other healthcare providers and allied health professionals (dietitians, nurses, nutritionists and researchers) who will learn the pathophysiology and mechanisms related to the role of nutrition in kidney disease and kidney health.

#### SAVE THE DATE

Nutritional and Dietary Management of Kidney Disease: A Patient Care Approach

We Are What We Eat: Learn How to Enfor Kidney Health through Nutrition and Diet

UCI Nephrology has teamed up with the nation's leading experts to leverage their interests and expertiss to provide insights on real-world clinical management and hands-on workshops for dietary approaches.

This is a full-day CME course for physicians (Nephrologits, Internist, Urologits and Family Practitioners) and other healthcare providers and all health professionals (dictilians, nurse, nurticionists), and researchers) who will learn the pathophysiology and mechanisms related to the role of nurtrition in kidney disease and kidney health.


#### **UCI Health**


Saturday, February 29, 2020 7:30 a.m. to 4:45 p.m.


UCI Health Medical Center Bldg. 53, Auditorium 101 The City Drive South Orange, CA 92868


ər more information, istine Fuentebella at <u>kfuenteb@uci.edu</u> | 714-456-5143

















- Higher weight is good in dialysis patients?
- Does higher mean higher "fat" or higher "muscle"?

















#### **Protein-Energy Wasting** RNM suggested (PEW) Diagnosis criteria→ Table 1 | Readily utilizable criteria for the clinical diagnosis of meeting report http://www.kidney-international.org PEW in AKI or CKD Criteria Serum Chemistry Serum chemistry Serum albumin < 3.8 g per 100 ml (Bramcresol Green)\* Serum prealbumin (transthyretin) < 30 mg per 100 ml (for A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney ER le dialysis patients only; levels may var patients with CKD stages 2-5)\* according el for patients with CKD stages 2–5)<sup>4</sup> Serum cholesterol < 100 mg per 100 m<sup>B</sup> disease D Fouque<sup>117</sup>, K Kalantar-Zadeh<sup>2,17</sup>, J Kopple<sup>7</sup>, N Cano<sup>3</sup>, P Chauveau<sup>4</sup>, L Cuppan<sup>5</sup>, H Franch<sup>6</sup>, G Guamien<sup>7</sup>, TA likize<sup>8</sup>, G Kaysen<sup>310</sup>, B Lindholm<sup>11</sup>, Z Massy<sup>12,13</sup>, W Mitch<sup>14</sup>, E Pineda<sup>15</sup>, P Stenvinkel<sup>11</sup>, A Trevinho-Becera<sup>15</sup> and C Wanner<sup>16</sup> **Body Mass** Body mass $BMI < 23^{b}$ Unintentional weight loss over time: 5% over 3 months or over 6 months Total body fat percentage **Muscle Mass** Muscle mass reduced muscle mass 5% over 3 m hs or 10% over 6 Muscle wastin months Reduced m relation to id-arm muscle circumference area<sup>c</sup> (reduction >10% in 50th percentile of reference population) Creati appearanced **Dietary Intake** ow DPI <0.80 g kg<sup>-1</sup>day<sup>-1</sup> for at least 2 months<sup>6</sup> for or <0.6 g kg<sup>-1</sup> day<sup>-1</sup> for patients with CKD stages 2-5 ow DEI <25 kcalkg<sup>-1</sup> day<sup>-1</sup> for at least 2 months<sup>6</sup> Uninte dialysis ents or $< 0.6 \text{ g kg}^{-1} \text{ d}$ al low DEI < 25 kcalkUninte Fouque, Kalantar-Zadeh, Kopple ... Wanner Kidney International 2008


17


18





# Low Albumin → Death igh Albumin → Survival















• The MIS has <u>10 components</u>, each with <u>4 levels</u> of severity: from 0 (normal) to 3 (very severe).


 The sum of all 10 DMS components: ranges from 0 (normal) to 30 (severely malnourished).


	MALITO HAHOA IA	FLAMMATION SCOR	L.
(A) Patients' related media	al history		
	dry weight (overall change	in past 3/6 months):	
0	1	2	1
No decrease in dry weight	Minor weight loss	Weight loss more than	Weight loss >5%
or weight loss <0.5 kg	(>0.5 kg but <1 kg)	one kg but <5%	
2- Dietary Intake:			
0	1	2	3
Good appetite and no	Somewhat sub-optimal	Moderate overall decrease	Hypo-caloric liquid to
deterioration of the dietary intake pattern	solid diet intake	to full liquid diet	starvation
3- Gastrointestinal (GI) sy	motoms:	1	
0			1
No symptoms with good	Mid symptoms, poor	Occusional vomiting or	Frequent diantea or
appetite	appetite or nauseated	modering GI symptoms	vomiting or severe
	occasionally		anorexia
4- Functional capacity (nu	tritionally related functional	I imp3irmont]:	
0	1	2	3
Normal to improved	Occasional difficulty with	Difficulty with otherwise	Bed/chair-ridden, or little
functional capacity, feeling	baseline ambulation, or feeling lined frequently	independent antivities (e.g. going to bathroom)	to no physical activity
	number of years on Dialysi	and the second s	
o controlog include			1
On dialysis less than one	Dialyzed for 1-4 years, or	Dailyand 34 years, or	Any severe, multiple co-
year and healthy otherwise	mild co-morbidity	moderate co-morbidity	morbidity (2 or more
	(excluding MCC <sup>*</sup> )	(including one MCC*)	MCC")
(B) Physical Exam (accord	ting to SGA criteria):		
6- Decreased fat stores or	loss of subcutaneous fat (t	pelow eyes, triceps, biceps, ches	
0	1	2	3
Normal (no change)	mild	moderate	Severe
7- Signs of muscle wastin		os, quadriceps, knee, interosseo	usk
0	1	2	3
Normal (no change)	mid	moderate	Severe
(C) Body mass index: 8-Body mass index: BMI	= Wt(kg), (Ht <sup>2</sup> (m)		
8-Body mass index: BMI		2	3
	BM8: 18-10.99 kg/m <sup>2</sup>	2 6MI: 16-17.99 kg/m <sup>2</sup>	3 BMI<16 kg/m <sup>2</sup>
8- Body mass index: BMI 0 BMI>20 kg/m <sup>2</sup>	BMI: 18-19.99 kg/m <sup>2</sup>		3 BMI<16 kg/m <sup>2</sup>
Body mass index: BMI 0 BMI>20 kg/m <sup>2</sup> (D) Laboratory Parameter	BMI: 18-19.99 kg/m <sup>2</sup>		3 BMI<16 kg/m <sup>2</sup>
8- Body mass index: BMI 0 BMI>20 kg/m <sup>2</sup>	BMI: 18-19.99 kg/m <sup>2</sup>	8MI: 16-17.99 kg/m <sup>2</sup>	3 BMI<16 kg/m <sup>2</sup>
Body mass index: BMI O BMI>20 kg/m <sup>2</sup> (D) Laboratory Parameter S- Serum albumin: 0	BAR 18-19-50 kg/m <sup>2</sup>	6Mt: 16-17.99 kg/m <sup>2</sup>	3
Body mass Index: BMI BMI>20 kg/m <sup>2</sup> BMI>20 kg/m <sup>2</sup> BMI>20 kg/m <sup>2</sup> Serum albumin: 0 Abumins 4.0 g/d.	BM: 18.19 59 kg/m <sup>2</sup> 5: Attumin: 3.5.3.9 g/d,	8MI: 16-17.99 kg/m <sup>2</sup>	3 BMI<15 kg/m <sup>2</sup> 3 Albumin: <3.0 g/di.
Body mass Index: BMI BMI>20 kg/m <sup>2</sup> BMI>20 kg/m <sup>2</sup> BMI>20 kg/m <sup>2</sup> Serum albumin: 0 Abumins 4.0 g/d.	BM: 18.19 59 kg/m <sup>2</sup> 5: Attumin: 3.5.3.9 g/d,	6Mt: 16-17.99 kg/m <sup>2</sup>	3
Body mass index: BMI 0 BMI220 kg/m <sup>2</sup> (D) Leboratory Parameter Serum abbumin: 0 Aloyme2-40 g/M. 10-Serum TIBC (total flor 0	846: 16.10.99 kg/m <sup>2</sup> 8: Altourine: 3.5-3.9 g/dL Binding Capacity): •	EAN: 16-17.99 kg/m <sup>2</sup>	3 Albumin: <3.0 g/dl. 3
Body mass Index: BMI BMI>20 kg/m <sup>2</sup> BMI>20 kg/m <sup>2</sup> BMI>20 kg/m <sup>2</sup> Serum albumin: 0 Abumins 4.0 g/d.	BM: 18.19 59 kg/m <sup>2</sup> 5: Attumin: 3.5.3.9 g/d,	6Mt: 16-17.99 kg/m <sup>2</sup>	3
Both mass Index: Bitl Bath mass Index: Bitl Bath 20 spim <sup>2</sup> (0) Leboratory Parameter Serum albumin: Anymma 40 gH. 10- Serum TIBC (total for TIBCs 250 mpld. )	Bit: 18-10 50 kg/m <sup>2</sup> 8: Altourne: 3 5-3 0 grit. Bins ing Capacity): A 1 190: 200-249 mg/d.	2 Albumin: 30-34 gist 2 TBC: 150-199 mg/dt	3 Albumin: <3.0 g/dl. 3
Boto mass index. Bit Bato mass index. Bit Bato 20 spin <sup>2</sup> (0) Laboratory Parameter Serum albumin: Anymex 40 pH. 10: Serum TIBC (total for TIBCs 250 mpld. )	846: 16.10.99 kg/m <sup>2</sup> 8: Altourine: 3.5-3.9 g/dL Binding Capacity): •	2 Albumin: 30-34 gist 2 TBC: 150-199 mg/dt	3 Albumin: <3.0 g/dl. 3
Body mass index- bit O(1)>20 spm <sup>2</sup> Secure abumin: O(2) Leboratory Parameter Secure abumin: O(2) Leboratory Parameter O(2) Leboratory Parameter O	BM: 16.19.99 kg/m <sup>2</sup> 5: Alturnin: 3.5.3.9 g/d. Binding Gapacity): 4 TBC: 200-249 mg/d. above: 10 components	2 Albumin: 30-34 girst 2 TBC: 150-199 mg/dt. (0-30):	3 Albumin: <3.0 g/d. 3 TiBC; <150 mg/dl.
Body mass index: BMI Of Laboratory Parameter Serum albumin: Of Laboratory Parameter Serum maturin: Of Laboratory Parameter Tel>2 or get, Total Score = sum of MCC Mairs Camerhia Com	BM: 16.19.99 kg/m <sup>2</sup> 5: Alturnin: 3.5.3.9 g/d. Binding Gapacity): 4 TBC: 200-249 mg/d. above: 10 components	SMI: 16-17.99 kpim       2       Albumin: 30-3.4 g/dg,       TBC: 150-199 mg/dg,       (0-30):       Valid More ALDS, severe CAD,	3 Albumin: <3.0 g/d. 3 TiBC; <150 mg/dl.


Kalantar-Zadeh et al; AJKD 2001
























#### IDPN Intra-Dialytic Parenteral Nutrition


- • Nutritional support therapy designed for hemodialysis patients
- Infusion of amino acids, dextrose and lipids during dialysis
- • Given three times/week during dialysis treatment
- Provides 700-1200 calories and 45-75 grams of protein/treatment


#### Improves


- Appetite
- Strength
- Overall well being/nutritional status
- Increases dry weight by building lean muscle mass
- Improves albumin level
























53

54

Essen waehrend Hemodialyse (meals during hemodialysis)







Essen waehrend Hemodialyse (meals during hemodialysis)







Essen waehrend Hemodialyse (meals during hemodialysis)



57





Essen waehrend Hemodialyse (meals during hemodialysis)



59

### Essen waehrend Hemodialyse Eating During Dialysis, Wurzburg, Germany





Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial








Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial


Connie M. Rhee<sup>1</sup>, Amy S. You<sup>1</sup>, Tara Koontz Parsons<sup>2</sup>, Amanda R. Tortorici<sup>1</sup>, Rachelle Bross<sup>3</sup>, David E. St-Jules<sup>3</sup>, Jennie Jing<sup>1</sup>, Martin L. Lee<sup>4</sup>, Debbie Benner<sup>5</sup>, Csaba P. Kovesdy<sup>67</sup>, Rajnish Mehrotra<sup>6</sup>, Joel D. Kopple<sup>6,810</sup> and Kamyar Kalantar-Zadeh<sup>12,4</sup>


Connie M. Rhee, Amy S. You, Tara Koontz Parsons, Amanda R. Tortorici, Rachelle Bross, David E. St-Jules, Jennie Jing, Martin L. Lee, Debbie Benner, Csaba P. Kovesdy, Rajnish Mehrotra, Joel D. Kopple and Kamyar Kalantar-Zadeh. Nephrol Dial Transplant (2017)














#### Investigators and Staff

- Elani Streja, MPH, PhD Connie M. Rhee, MD, MSc

- Hamid Moradi, MD Wei Ling Lau, MD Joline Chen, MD, MPH Foad Ahamdi, MD
- Paungpaga Lettdumrongluk, MD Yoshitsugu Obi, MD Melissa Soohoo, MPH Bryan Shapiro, MPH

- Amanda Brown, RD Tracy Nakata

ena

- Collaborators: Csaba P. Kovesdy, MD Rajnish Mehrotra, MD

- Rajnish Mehrotra, MD Joel D Kopple, MD Matthew Budoff, MD Steven S. Jacobsen, MD, PhD Rajiv Saran, MD, MSc. Miklos Z. Molnar, MD, PhD Jongha Park, MD Daniel Gillen, PhD Danh Nguyen, PhD Allen Nissenson, MD, Steven Brunelli, MD, MS